Bristol Myers, Exelixis scored a kidney cancer combo win. But is there room for their duo on the market?
admin 21st April 2020 Uncategorised 0Bristol Myers Squibb and Exelixis have a potential kidney cancer contender on their hands with their Opdivo-Cabometyx combo. But the duo will have to meet a “high bar” to gain traction in the crowded field, one analyst says. More: Bristol
read more